Unicycive Therapeutics (NASDAQ:UNCY) just reported results for the second quarter of 2024.
- Unicycive Therapeutics reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -19 cents.
- The company did not report any revenue for the quarter.